MST-188

DRUG3 trials

Sponsors

Mast Therapeutics, Inc.

Conditions

Acute Limb IschemiaSickle Cell DiseaseVaso-occlusive Crisis

Phase 2

Evaluation of MST-188 in Acute Lower Limb Ischemia

TerminatedNCT02093468

Mast Therapeutics, Inc.Acute Limb Ischemia

Start: 2014-06-30Updated: 2015-12-15

Phase 3

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

CompletedNCT01737814

Mast Therapeutics, Inc.Sickle Cell Disease, Vaso-occlusive Crisis

Start: 2013-05-31Updated: 2016-10-28

Evaluation of Repeat Administration of Purified Poloxamer 188

CompletedNCT02449616

Mast Therapeutics, Inc.Sickle Cell Disease

Start: 2015-06-30Updated: 2016-10-28

Related Papers

Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease

JAMA2021-04-2041 citations